Audit Findings on Adverse Event Reporting Delays at Investigator Sites
Audit Findings on Adverse Event Reporting Delays at Investigator Sites Adverse Event Reporting Delays in Clinical Trial Site Audits Introduction: Why Timely Adverse Event Reporting Matters Adverse event (AE) and serious adverse event (SAE) reporting is a cornerstone of subject safety in clinical trials. Regulators, including the FDA, EMA, and MHRA, consider delayed or incomplete…
Read More “Audit Findings on Adverse Event Reporting Delays at Investigator Sites” »